SL
Steve Lichtman is a seasoned healthcare analyst specializing in the medical technology industry, with a focus on ophthalmology, diabetes, and orthopedics. He joined William Blair in November 2025 after a long tenure at Oppenheimer & Co., where he was a Managing Director and Senior Equity Research Analyst. Lichtman holds a B.A. in economics and public policy studies from Duke University and an M.B.A. from New York University.
No chart yet. A chart needs 8 resolved predictions, and Steve has 1. The predictions themselves are below.
SORT
✓
Initiates Outperform rating with a price target of $275 for Penumbra.
December 17, 2024call #1Stock RatingCorrect
85
SCORE
◇
Initiates Outperform rating with a price target of $75 for Inari Medical.
December 17, 2024Stock RatingNot settleable
—
SCORE
◇
Trump will be impeached.
November 17, 2016politicsimpeachmentNo verdict
—
SCORE